Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q3 2025 value amounting to $105000.0.

  • Whitehawk Therapeutics' Other Accumulated Expenses changed N/A to $105000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $105000.0, marking a year-over-year change of. This contributed to the annual value of $650000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Other Accumulated Expenses of $105000.0 as of Q3 2025.
  • In the past 5 years, Whitehawk Therapeutics' Other Accumulated Expenses registered a high of $1.5 million during Q3 2021, and its lowest value of $10805.0 during Q2 2021.
  • Its 4-year average for Other Accumulated Expenses is $450804.8, with a median of $305000.0 in 2021.
  • Examining YoY changes over the last 5 years, Whitehawk Therapeutics' Other Accumulated Expenses showed a top increase of 697632.42% in 2021 and a maximum decrease of 6387.86% in 2021.
  • Whitehawk Therapeutics' Other Accumulated Expenses (Quarter) stood at $496000.0 in 2021, then skyrocketed by 34.68% to $668000.0 in 2022, then fell by 2.69% to $650000.0 in 2024, then plummeted by 83.85% to $105000.0 in 2025.
  • Its Other Accumulated Expenses stands at $105000.0 for Q3 2025, versus $114000.0 for Q2 2025 and $650000.0 for Q4 2024.